Ann: Entitlement Offer to raise approximately $3.2 million, page-18

good points VA.

if people look passed the share price, there is tantalising value with just their lead asset CDH17:
- world first 3rd Gen CART
- CART developed by the pioneers of CART at UPenn
- compelling preclinical data against 7 GI cancer lines
- GI cancer market alone is worth US$25bn per annum
- very exciting early signals of efficacy with 100% disease control rate at the lowest dosage level
- scans and blood tests are showing a text book response with excellent expansion and persistence
- potential signs that patient 2 may move from stable disease to partial response
- enquiries from other cell therapy companies
- relative performance of CHM therapy compared to claudin 18.2 second Gen cart (which has been described as a blockbuster) may be better based on persistence of CART